Extension study following the phase I/II clinical study of CT-P13 in the patients with rheumatoid arthritis
Phase 4
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-jRCT1080222652
- Lead Sponsor
- ippon Kayaku Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
(1) Patients who have completed final observation after 54-week administration in the phase I/II clinical study and whose symptoms are stable.
(2) Patients for whom administration of CT-P13 is deemed appropriate as of the end of final observation after 54-week administration in the phase I/II clinical study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method